A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Latest Information Update: 20 Feb 2019
At a glance
- Drugs Isavuconazole (Primary) ; Isavuconazole (Primary) ; Isavuconazonium (Primary) ; Isavuconazonium (Primary) ; Caspofungin; Voriconazole
- Indications Candidaemia; Invasive bronchopulmonary aspergillosis; Invasive candidiasis
- Focus Registrational; Therapeutic Use
- Acronyms ACTIVE
- Sponsors Astellas Pharma
- 05 Oct 2018 Results published in the Clinical Infectious Diseases
- 22 May 2017 Planned locations for this trial also included Colombia, Egypt, Netherlands, Poland, Turkey, UK.
- 25 Apr 2017 Results assessing correlation between exposure measures and efficay outcomes presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.